These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

797 related items for PubMed ID: 34922381

  • 1. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, Zillikens MC, Body JJ.
    J Clin Endocrinol Metab; 2022 Apr 19; 107(5):1441-1460. PubMed ID: 34922381
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M.
    Cancer Treat Rev; 2018 Sep 19; 69():177-187. PubMed ID: 30055439
    [Abstract] [Full Text] [Related]

  • 4. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan.
    Kunihara T, Tohmori H, Tsukamoto M, Kobayashi M, Okumura T, Teramoto H, Hamasaki T, Yamasaki T, Nakagawa T, Okimoto N, Fujiwara S.
    Osteoporos Int; 2023 Jun 19; 34(6):1101-1109. PubMed ID: 37002373
    [Abstract] [Full Text] [Related]

  • 5. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB.
    Oral Maxillofac Surg Clin North Am; 2015 Nov 19; 27(4):509-16. PubMed ID: 26362367
    [Abstract] [Full Text] [Related]

  • 6. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G, Manfredi M, Giovannacci I, Mergoni G, Sarraj A, Mureddu M, Giunta G, Bonanini M, Meleti M, Vescovi P.
    Minerva Stomatol; 2017 Aug 19; 66(4):135-140. PubMed ID: 28497661
    [Abstract] [Full Text] [Related]

  • 7. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T.
    Tohoku J Exp Med; 2019 Feb 19; 247(2):75-86. PubMed ID: 30713280
    [Abstract] [Full Text] [Related]

  • 8. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M, Kuroshima S, Sawase T.
    Int J Implant Dent; 2021 May 14; 7(1):47. PubMed ID: 33987769
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Emerging antiresorptive medications and their potential implications for dental surgeries.
    Aminoshariae A, Donaldson M, Horan M, Mackey SA, Kulild JC, Baur D.
    J Am Dent Assoc; 2022 Jul 14; 153(7):649-658. PubMed ID: 35277242
    [Abstract] [Full Text] [Related]

  • 11. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E, Bamias A.
    Eur J Cancer Care (Engl); 2017 Nov 14; 26(6):. PubMed ID: 29063702
    [Abstract] [Full Text] [Related]

  • 12. A systematic review of metastatic cancer presenting in osteonecrosis of the jaws (MC-ONJ) in patients undergoing antiresorptive and/or antiangiogenic therapy for skeletal-related adverse events.
    Sacco R, Woolley J, Yates J, Calasans-Maia MD, Akintola O, Patel V.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Jun 14; 131(6):650-659. PubMed ID: 33518491
    [Abstract] [Full Text] [Related]

  • 13. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V, Campisi G, Bedogni A.
    Support Care Cancer; 2022 Sep 14; 30(9):7047-7051. PubMed ID: 35312858
    [Abstract] [Full Text] [Related]

  • 14. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D.
    Reumatismo; 2017 May 22; 69(1):9-15. PubMed ID: 28535616
    [Abstract] [Full Text] [Related]

  • 15. The Prevention of Medication-related Osteonecrosis of the Jaw.
    Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P.
    Dtsch Arztebl Int; 2017 Feb 03; 114(5):63-69. PubMed ID: 28241916
    [Abstract] [Full Text] [Related]

  • 16. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
    Galis B, Zajko J, Hirjak D, Vanko L, Kupcova I, Jurkemik J, Gengelova P, Mikuskova K, Halmova K, Riznic M, Czako L.
    Bratisl Lek Listy; 2017 Feb 03; 118(12):724-731. PubMed ID: 29322803
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
    Otto S, Aljohani S, Fliefel R, Ecke S, Ristow O, Burian E, Troeltzsch M, Pautke C, Ehrenfeld M.
    Medicina (Kaunas); 2021 May 09; 57(5):. PubMed ID: 34065104
    [Abstract] [Full Text] [Related]

  • 20. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw.
    J Clin Densitom; 2017 May 09; 20(1):8-24. PubMed ID: 27956123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.